INMED PHARMACEUTICALS INC. Stock-Based Compensation
INMED PHARMACEUTICALS INC. (INM) reported Stock-Based Compensation of $106.87 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $22.63K, a 15.35% decline year-over-year.
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $38.77K, a 4.16% decline year-over-year.
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $25.26K, a 9.09% increase year-over-year.
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $20.20K, a 30.24% decline year-over-year.
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for fiscal 2023 was $278.15K, a 60.14% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for fiscal 2022 was $697.89K, a 14.37% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for fiscal 2021 was $610.19K, a 38.64% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. share-based payment arrangement, noncash expense for fiscal 2020 was $994.40K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.63K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $61.40K derived: sum of 2 quarters · filed 2026-09-09 | $86.66K derived: sum of 3 quarters · filed 2026-09-09 | $106.87K S-4/A · filed 2026-09-09 |
| 2026-03-31 | $38.77K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $64.03K derived: sum of 2 quarters · filed 2026-07-02 | $84.24K S-4 · filed 2026-07-02 | $110.97K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-12-31 | $25.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $45.47K 10-Q · filed 2026-02-11 | $72.20K derived: sum of 3 quarters · filed 2026-09-09 | $112.65K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-09-30 | $20.20K 10-Q · filed 2025-11-06 | $46.94K derived: sum of 2 quarters · filed 2026-09-09 | $87.39K derived: sum of 3 quarters · filed 2026-09-09 | $110.55K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-06-30 | $26.73K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $67.18K derived: sum of 2 quarters · filed 2026-09-09 | $90.34K derived: sum of 3 quarters · filed 2026-09-09 | $119.31K S-4/A · filed 2026-09-09 |
| 2025-03-31 | $40.45K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $63.61K derived: sum of 2 quarters · filed 2026-07-02 | $92.58K S-4 · filed 2026-07-02 | $131.53K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-12-31 | $23.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $52.12K 10-Q · filed 2026-02-11 | $91.08K derived: sum of 3 quarters · filed 2026-07-02 | $146.38K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-09-30 | $28.96K 10-Q · filed 2025-11-06 | $67.92K derived: sum of 2 quarters · filed 2026-07-02 | $123.22K derived: sum of 3 quarters · filed 2026-07-02 | $141.49K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-06-30 | $38.95K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $94.26K derived: sum of 2 quarters · filed 2026-07-02 | $112.52K derived: sum of 3 quarters · filed 2026-07-02 | $137.71K S-4 · filed 2026-07-02 |
| 2024-03-31 | $55.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $73.57K derived: sum of 2 quarters · filed 2025-05-12 | $98.76K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $18.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $43.45K 10-Q · filed 2025-02-12 | ||
| 2023-09-30 | $25.19K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $278.15K 10-K · filed 2024-09-30 | |||
| 2023-03-31 | $50.36K 10-Q · filed 2023-05-15 | $121.00K derived: sum of 2 quarters · filed 2023-05-15 | $237.68K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-12-31 | $70.64K 10-Q · filed 2023-02-17 | $187.32K 10-Q · filed 2024-02-13 | ||
| 2022-09-30 | $116.68K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $697.89K 10-K · filed 2022-09-23 | |||
| 2022-03-31 | $195.09K 10-Q · filed 2023-05-15 | $409.86K derived: sum of 2 quarters · filed 2023-05-15 | $521.01K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $214.78K 10-Q · filed 2023-02-17 | $325.92K 10-Q · filed 2023-05-15 | ||
| 2021-09-30 | $111.14K 10-Q · filed 2023-02-17 | |||
| 2021-06-30 | $610.19K 10-K · filed 2022-09-23 | |||
| 2021-03-31 | $207.30K 10-Q · filed 2022-05-13 | $303.94K derived: sum of 2 quarters · filed 2022-05-13 | $389.34K derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $96.63K 10-Q · filed 2022-02-14 | $182.04K 10-Q · filed 2022-05-13 | ||
| 2020-09-30 | $85.41K 10-Q · filed 2022-02-14 | |||
| 2020-06-30 | $994.40K 10-K · filed 2021-09-24 | |||
| 2020-03-31 | $203.87K 10-Q · filed 2021-05-13 | $487.82K derived: sum of 2 quarters · filed 2021-05-13 | $838.30K derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $283.95K 10-Q · filed 2021-02-11 | $634.43K 10-Q · filed 2021-05-13 | ||
| 2019-09-30 | $350.48K 10-Q · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |